[BGMD] BG Medicine, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances

Market Capitalization: 3.29 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 0.05 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart BGMD

Refresh chart

Strongest Trends Summary For BGMD

BGMD is in the long-term down -65% in 3 years and down -100% below S&P in 13 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BG Medicine, Inc., a diagnostics company, develops and commercializes novel cardiovascular diagnostic tests to address unmet medical needs in the United States. The company offers BGM Galectin-3 test, a novel assay for measuring galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of patients diagnosed with heart failure; and CardioSCORE test, which is designed to identify individuals at high risk for cardiovascular events, such as heart attack and stroke. It has license, development, and commercialization agreements with Abbott Laboratories, Alere Inc., bioMérieux SA, and Siemens Healthcare Diagnostics Inc. for the development of galectin-3 test on their automated instrument platforms; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded

Fundamental Ratios
Shares Outstanding8.66 M EPS-0.82 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -45.31% Sales Growth - Q/Q-21.12% P/E-0.46
P/E To EPS Growth P/S1.32 P/BV-5.81 Price/Cash Per Share
Price/Free Cash Flow ROA-279.27% ROE1277.92% ROI
Current Ratio0.74 Quick Ratio0.65 Long Term Debt/Equity Debt Ratio-5.42
Gross Margin65.51% Operating Margin-268.45% Net Profit Margin-291.07% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.12 M Cash From Investing Activities Cash From Operating Activities-1.39 M Gross Profit290 K
Net Profit-1.35 M Operating Profit-1.26 M Total Assets2.59 M Total Current Assets2.27 M
Total Current Liabilities3.07 M Total Debt1.86 M Total Liabilities3.16 M Total Revenue440 K
Technical Data
High 52 week0.07 Low 52 week0.01 Last close0.01 Last change0%
RSI43.24 Average true range Beta0.64 Volume18.28 K
Simple moving average 20 days-38.89% Simple moving average 50 days-37.76% Simple moving average 200 days-58.09%
Performance Data
Performance Week-50% Performance Month-50% Performance Quart-60% Performance Half-50%
Performance Year-80% Performance Year-to-date-53.05% Volatility daily26.86% Volatility weekly60.06%
Volatility monthly123.08% Volatility yearly426.37% Relative Volume104.01% Average Volume4.47 K
New High New Low


2016-04-08 13:04:23 | BG MEDICINE, INC. Financials

2016-04-04 17:02:19 | BG MEDICINE, INC. Files SEC form 10-K, Annual Report

2016-03-31 17:06:16 | BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events

2016-02-04 17:05:52 | BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers

2015-12-23 08:17:34 | BG Medicine Withdraws 510k Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test

2015-12-23 07:58:52 | BG MEDICINE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2015-12-04 17:04:14 | BG MEDICINE, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibit

2015-11-30 07:50:39 | BG MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

2015-11-27 10:32:16 | BG Medicine, Inc. Earnings Q3, 2015

2015-11-23 16:25:21 | BG MEDICINE, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;

2015-11-20 17:02:50 | BG MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

2015-11-17 13:57:42 | Edited Transcript of BGMD earnings conference call or presentation 17-Nov-15 1:30pm GMT

2015-11-17 08:02:45 | BG MEDICINE, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statemen

2015-11-16 17:16:40 | BG MEDICINE, INC. Files SEC form 10-Q, Quarterly Report

2015-11-05 08:33:00 | BG Medicine Due Diligence Report: Quietly Making Headway - Broad Street Alerts

2015-08-21 09:13:00 | 5 Stocks Ready for Breakouts

2015-08-12 12:50:21 | Psychemedics Corp. Earnings Q2*, 2015

2015-07-08 17:00:28 | BG Medicine Announces One-for-Four Reverse Stock Split